NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Acesion Pharma

Acesion Pharma

Private
CopenhagenHealthcare & Life Scienceshttps://acesionpharma.com/

Last Round

Series B

Sep 26, 2023

Total Funding Raised

$63.47M

Company Overview

Acesion Pharma is a biotechnology company that develops selective small-molecule inhibitors targeting SK channels to treat atrial fibrillation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

atrial fibrillationAFibsmall molecule inhibitorSK channel inhibitorbiopharmaceuticaldrug discoveryclinical-stage biotechcardiac rhythmdrug developmentbiotech startupclinical trialtherapeutic candidatepreclinical researchout-licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Acesion Pharma Comparables

Compare Acesion Pharma with similar companies based on industry and business-model similarity.

Acesion Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Thryv Therapeutics
81%
Revadix
78%
HUYA Bioscience International
78%

Acesion Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 26, 2023
GrantMar 12, 2019
Series AOct 31, 2016
VC RoundDec 17, 2014
SeedDec 15, 2011
Seed
Dec 1, 2010

Key People

Founding team and executive leadership

Ulrik Sørensen

COO And Co-Founder

Founding Team

Anders Gaarsdal Holst

Chief Executive Officer, Chief Medical Officer

Executive Team

Torgeir Vaage

Chief Financial Officer

Executive Team

Acesion Pharma Investors

Notable investors and investment history

Acesion Pharma investors
InvestorRounds
Innovation Fund DenmarkGrant
RM Global PartnersSeries B
Novo HoldingsVC Round, Series B, Seed, Series A
Canaan PartnersSeries B
SEED CapitalSeries A
Seed CapitalSeed
FC CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 6, 2026

    Developing novel mechanism for rhythm control of atrial fibrillation.

  • Mar 12, 2019

    $760K grant received from Innovation Fund Denmark.

Acesion Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Acesion Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Acesion Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersCopenhagen
Employee Range22
Year Founded2011
Last FundingSep 26, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.